8-K: Vera Therapeutics Reports Positive Phase 3 Atacicept Data for IgA Nephropathy, Paving Way for Accelerated Approval Submission

Vera Therapeutics announced positive 36-week results from its ORIGIN Phase 3 clinical trial of atacicept in adult patients with IgA nephropathy (IgAN), demonstrating a statistically significant reduction in proteinuria and a favorable safety profile, with plans for accelerated FDA approval submission in Q4 2025.

Summary

• Vera Therapeutics announced positive 36-week data from its ORIGIN Phase 3 clinical trial of atacicept in adult patients with immunoglobulin A nephropathy (IgAN) on June 2, 2025.
• Atacicept, a potential best-in-class dual inhibitor of B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), met its primary efficacy endpoint.
• Participants treated with atacicept (n=103) achieved a 46% reduction from baseline in proteinuria, measured by 24-hour urine protein-to-creatinine ratio (UPCR).
• This represents a statistically significant and clinically meaningful 42% reduction in UPCR compared to placebo (p<0.0001) at week 36.
• The safety profile of atacicept was favorable and comparable to placebo, with a lower incidence of serious adverse events (0.5% vs. 5%) and drug discontinuations (1% vs. 4%) compared to placebo.
• The company plans to share these results with the U.S. Food and Drug Administration (FDA) in the coming weeks and submit a Biologics License Application (BLA) for accelerated approval in IgAN to the FDA in the fourth quarter of 2025.
• A projected commercial launch, if approved, is anticipated in 2026.
• The ORIGIN Phase 3 trial will continue in a blinded manner to evaluate changes in kidney function (eGFR) over two years, with full results expected in 2027.
• As of March 31, 2025, Vera Therapeutics reported approximately $590 million in cash, cash equivalents, and marketable securities, with approximately 63.7 million shares outstanding as of May 1, 2025.

Sentiment

Score: 9

Explanation: The document reports highly positive Phase 3 clinical trial results for atacicept, meeting its primary endpoint with statistical significance and a favorable safety profile. This positions the company for accelerated FDA approval and potential commercial launch, indicating strong progress towards addressing a significant unmet medical need in IgAN. The financial position is also strong.

Positives

• Atacicept achieved a statistically significant and clinically meaningful 42% reduction in proteinuria (UPCR) compared to placebo (p<0.0001) at week 36 in the ORIGIN Phase 3 trial, exceeding the 35% reduction observed in Phase 2b.
• The safety profile of atacicept was favorable and comparable to placebo, with a lower rate of serious adverse events and drug discontinuations in the atacicept arm.
• Atacicept has received FDA Breakthrough Therapy Designation for IgAN, indicating potential for substantial improvement over available therapies.
• The company plans to submit a Biologics License Application (BLA) for accelerated approval in Q4 2025, potentially leading to a commercial launch in 2026.
• Atacicept is positioned as a potential best-in-class, disease-modifying dual inhibitor of BAFF and APRIL, targeting the source of IgAN.
• Long-term Phase 2b data showed eGFR stabilization consistent with the general population and reductions in Gd-IgA1 and hematuria, supporting disease modification.
• Nephrologists surveyed viewed atacicept as the 'Most Desired IgAN Pipeline Agent' (73% preference among familiar respondents) and prefer its dual BAFF/APRIL mechanism over APRIL-only therapies.
• The company maintains a strong financial position with approximately $590 million in cash, cash equivalents, and marketable securities as of March 31, 2025.

Risks

• Actual results may differ materially from forward-looking statements due to various risks and uncertainties.
• Risks related to the regulatory approval process, including the possibility that the FDA may not grant accelerated approval or full approval.
• Results of earlier clinical trials (e.g., Phase 2b) may not be replicated or obtained in later clinical trials (e.g., full Phase 3 results).
• Preliminary or interim results (like the 36-week data) may not be predictive of final study results (e.g., two-year eGFR data).
• General business risks and uncertainties associated with the company's operations.
• The impact of macroeconomic and geopolitical events on the company's business and clinical development.

Future Outlook

Vera Therapeutics plans to submit a Biologics License Application (BLA) for accelerated approval of atacicept in IgAN to the FDA in the fourth quarter of 2025, with a projected commercial launch in 2026, if approved. The ORIGIN Phase 3 trial will continue to evaluate kidney function over two years, with full results expected in 2027. The company also intends to expand atacicept's development pipeline into additional autoimmune kidney diseases and other autoimmune indications, including initiating the PIONEER Phase 2 basket trial for expanded IgAN and anti-PLA2R & anti-nephrin podocytopathies.

Management Comments

• Richard Lafayette, M.D., F.A.C.P., Professor of Medicine, Nephrology and Director of the Glomerular Disease Center at Stanford University Medical Center, and a primary investigator for ORIGIN 2b and ORIGIN 3, stated: 'These results convincingly demonstrate the impact of atacicept to reduce proteinuria. If approved, we believe that atacicept has the potential to advance the standard of care in IgAN as the first dual BAFF/APRIL inhibitor.'
• Marshall Fordyce, M.D., Founder and CEO of Vera Therapeutics, commented: 'We currently plan to submit a BLA for atacicept in IgAN to the FDA in the fourth quarter of this year, which may allow for US approval and commercial launch in 2026. We are grateful for the ongoing commitment of the study participants, their families and caregivers, the study investigators and staff, our research partners, and the Vera team for their commitment and dedication to this important research. Vera aspires to evolve the practice of kidney medicine with the hope that, one day, patients may no longer face a future of dialysis or transplantation. Vera is poised for potential commercial launch of atacicept in 2026 and to pursue development in additional indications in other autoimmune kidney diseases and beyond.'
• Bonnie Schneider, Director and Cofounder of the IgA Nephropathy Foundation, expressed: 'I'm thrilled with the progress that is being made in developing new treatments for patients.'

Industry Context

IgA Nephropathy (IgAN) is a serious autoimmune kidney disease driven by B-cell activation and immune complex formation, leading to kidney damage and a high risk of end-stage kidney disease. The nephrology market, particularly for rare kidney diseases like IgAN, is characterized by high unmet medical need and a lack of innovative, disease-modifying therapies beyond supportive care. The emergence of dual BAFF/APRIL inhibitors like atacicept represents a potential paradigm shift, as they target the underlying immunological drivers of the disease, offering the promise of precision modulation of B cells and autoantibodies. This market is considered ripe for disruption, with potential for premium pricing for effective new treatments, as evidenced by the high annual prices of recently approved IgAN therapies.

Comparison to Industry Standards

• Atacicept's 42% reduction in UPCR compared to placebo at week 36 is noted as a 'deeper reduction than observed in Phase 2b (35%)' and is highlighted as the 'first Phase 3 clinical trial in IgAN to demonstrate this magnitude of UPCR reduction compared to placebo at week 36.'
• The document references other approved IgAN therapies and their annual prices: Filspari ($566,500), Tarpeyo ($162,500 for 9-month course, $213,010 for 12-month), Vanrafia ($158,716), and Fabhalta ($151,259), suggesting a high-value market for effective treatments.
• In a survey with nephrologists, atacicept was viewed as the 'Most Desired IgAN Pipeline Agent' by 73% of familiar respondents, outperforming other pipeline agents like sibeprenlimab (68%), povetacicept (48%), zigakibart (43%), ravulizumab (35%), and IONIS-FB-LRx (30%).
• Nephrologists prefer dual BAFF/APRIL inhibition over APRIL-only mechanisms of action for IgAN, attributing dual action to addressing the source of the disease and being applicable at lower proteinuria thresholds.
• Key drivers of nephrologist preference for atacicept include its eGFR stabilization data from Phase 2b, its mechanism of action as a disease-modifying therapy, the availability of long-term (96-week) data, and its appropriateness for patients with UPCR >1 g/g and eGFR decline.

Stakeholder Impact

• **Shareholders:** Highly positive clinical trial results are likely to significantly increase investor confidence and potentially lead to a substantial increase in share price, given the clear path to market and strong market potential.
• **Patients with IgAN:** The positive results offer significant hope for a new, potentially best-in-class, disease-modifying treatment that could reduce proteinuria and stabilize kidney function, potentially delaying or preventing dialysis and transplantation.
• **Employees:** Positive trial results and a clear regulatory pathway likely boost morale and job security, as the company moves closer to commercialization.
• **Healthcare Providers (Nephrologists):** The data supports atacicept as a highly desirable and effective treatment option, potentially advancing the standard of care for IgAN patients.
• **Regulatory Authorities (FDA):** The company's plans for accelerated approval submission will initiate a review process for a potentially significant new therapy for IgAN.

Next Steps

• Share ORIGIN Phase 3 36-week results with the U.S. Food and Drug Administration (FDA) in the coming weeks.
• Submit full ORIGIN Phase 3 results for presentation at the American Society of Nephrology (ASN) Kidney Week.
• Submit a Biologics License Application (BLA) for accelerated approval for atacicept in IgAN to the FDA in the fourth quarter of 2025.
• Continue the ORIGIN Phase 3 trial in a placebo-controlled blinded manner to evaluate the change in kidney function (eGFR) over two years, with completion expected in 2027.
• Pursue development of atacicept in additional indications in other autoimmune kidney diseases and beyond.
• Initiate the PIONEER Phase 2 basket trial in expanded IgAN and anti-PLA2R & anti-nephrin podocytopathies this quarter.

Key Dates

Recommendation

Keywords

IgA Nephropathy, IgAN, Atacicept, ORIGIN Phase 3, Clinical Trial, Proteinuria Reduction, UPCR, BAFF/APRIL Inhibitor, Biologics License Application, FDA Accelerated Approval, Kidney Disease, Autoimmune Disease, Biotechnology, Drug Development, Renal Medicine